Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.16 Per Share

Brokerages expect that Endocyte, Inc. (NASDAQ:ECYT) will report ($0.16) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Endocyte’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.15). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which would indicate a positive year-over-year growth rate of 38.5%. The firm is expected to issue its next quarterly earnings results on Friday, March 9th.

On average, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.25) to ($1.23). For the next fiscal year, analysts forecast that the company will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Endocyte.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The company had revenue of $0.03 million during the quarter. Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The company’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS.

A number of brokerages recently issued reports on ECYT. Cowen restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. ValuEngine upgraded shares of Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd.

In other Endocyte news, insider Philip S. Low sold 50,511 shares of the business’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.41, for a total transaction of $222,753.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Christopher P. Leamon sold 23,231 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the sale, the vice president now owns 150,579 shares of the company’s stock, valued at approximately $758,918.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 124,253 shares of company stock valued at $562,591. Insiders own 14.86% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its stake in Endocyte by 34.1% during the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares during the last quarter. FMR LLC increased its stake in Endocyte by 0.9% during the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after purchasing an additional 31,168 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Endocyte by 1,064.3% during the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares during the last quarter. Hedge funds and other institutional investors own 17.58% of the company’s stock.

Shares of Endocyte (NASDAQ:ECYT) traded down $0.11 during trading hours on Friday, hitting $4.09. 704,426 shares of the company were exchanged, compared to its average volume of 460,083. The company has a market capitalization of $178.82, a price-to-earnings ratio of -3.03 and a beta of 2.20. Endocyte has a fifty-two week low of $1.17 and a fifty-two week high of $6.55.

ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.16 Per Share” was reported by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/brokerages-anticipate-endocyte-inc-ecyt-will-announce-earnings-of-0-16-per-share/1821586.html.

Endocyte Company Profile

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.